Here are four updates on GI companies from the past week:
Allergan Director Chris Bodline purchased 3,030 shares of company stock Dec. 7, while CNBC analyst Jim Cramer criticized the company comparing it to the booming cryptocurrency Bitcoin.
Vizinet awarded Karl Storz Endoscopy-America's Vitom 3D system a 2017 Innovative Technology designation.
Mallinckrodt will acquire Sucampo Pharmaceuticals' commercial and development assets for approximately $1.2 billion, pending regulatory approval.
Exact Sciences President and CEO Kevin Conroy sold 123,513 shares at an average price of $52.58 per share Dec. 22, netting approximately $6.5 million.